Regenxbio is set to resubmit its gene therapy application for Hunter syndrome following a significant shift in the FDA’s stance on drug approvals. This decision comes as the agency seeks to address a backlog of rejections that have been criticized for contradicting prior agreements made with pharmaceutical companies during the tenure of former Commissioner Scott Gottlieb.
The FDA’s recent actions signal a potential easing of regulatory hurdles that have plagued the industry, particularly for innovative therapies. By reconsidering previously rejected applications, the agency may be attempting to restore confidence among drug developers and investors, indicating a more collaborative approach moving forward.
This development could have far-reaching implications for the gene therapy sector, as it may encourage other companies to pursue resubmissions or new applications, fostering a more favorable environment for innovation. As the FDA continues to refine its review processes, stakeholders will be closely monitoring how these changes impact the approval landscape for complex therapies.
Use the database as your supply chain compass →
